The Minnesota Heart Survey examined trends of Q wave and non-Q wave acute myocardial infarction (AMI) using a 50% random sample of all hospital discharges of community surveillance programs reported decreases in case-fatality rates over time and suggested that the observed decline in CHD mortality rates may reflect decreases in out-of-hospital coronary deaths or improved in-hospital case-fatality rates.2,4,6
C oronary heart disease (CHD) mortality rates have decreased 41% in the past 20 years, but acute CHD admission rates have not decreased similarly. The Minnesota Heart Survey (MHS) found that age-adjusted attack rates for definite myocardial infarction (MI) were similar in 1970 and 1980 (174.2 versus 179.9 per 100,000, respectively).' The Worcester Heart Attack Study reported increased rates of initial and recurrent acute myocardial infarctions (AMIs) between 1975 and 1981.2. 3 The Mayo Clinic study of CHD in residents of Rochester, Minn., reported decreased incidence rates of initial MI for men but increased rates for women between 1950 and 1982.4, All three of these Edlavitch et al Minnesota Heart Survey 493
The MHS was initiated in 1979 in the seven-county Twin Cities metropolitan area to investigate the causes of declining cardiovascular disease mortality rates by monitoring trends in community CHD morbidity, mortality, and risk factors. Trends of in-hospital attack and case-fatality rates for patients with AMI and stroke have been reported for 1970 and 1980. 1, 6 MHS findings are used to investigate trends in Q wave and non-Q wave AMI attack, case-fatality, and longterm survival rates in 1970 and 1980.
Methods The MHS has been described in detail by Gillum et al. 78 The population of the Twin Cities metropolitan area was 1, 874, 380 
Chest Pain
History of chest pain was defined as the presence or absence of typical cardiac chest pain in the hospital record. When the notes of different health-care providers were inconsistent determinators of presence or absence of chest pain, a hierarchical rule was applied; the hierarchy was attending physician, resident, intern, and then nurse.
Enzymes
Although all four enzyme levels were abstracted from the hospital record, only AST and LDH were used for the standard algorithm. Levels of AST and LDH were considered in the diagnostic algorithm as follows. For AST or LDH, a peak value exceeding twice the upper limit of the laboratory normal was considered abnormal unless the patient's record showed active liver disease, trauma within 1 week of admission, or surgery. If either of the two enzymes were abnormal, the individual was considered to have abnormal enzymes.
To further examine trends in AMI rates, we also calculated attack rates using CPK and CPK-MB as well as AST and LDH. CPK-MB was coded as present or absent by the laboratories or considered present if the value was above the upper limit of normal. Presence of CPK-MB, regardless of liver disease, trauma, or surgery, was considered abnormal. In these analyses, if any of the four enzymes was abnormal, the individual was considered to have abnormal enzymes.
Electrocardiogram Coding
All ECGs up to a maximum of 12 were copied and sent to the Minnesota coding center for visual Minnesota reading.11 When more than 12 recordings were available, the first six and the last six by date and time were used. The Minnesota code Q wave and non-Q wave classifications for ECG patterns are presented in the "Appendix." Q code criteria. Criteria for a Q wave pattern requires either the appearance of new diagnostic Minnesota Q codes or change from a minor Q code to a diagnostic Minnesota Q code accompanied by new T wave inversion, new ST elevation, or new ST depression. Q code and ST-T changes must occur in the same lead group (see "Appendix"). Among the ECG patterns shown in the "Appendix," only evolving diagnostic was considered sufficient to document AMI by itself. A diagnostic Q code on the baseline record in any lead group precluded this latter diagnosis.
Non-Q code criteria. The "Appendix" also displays the criteria used for non-Q wave AMI. This determination was made when there were no measurable Q waves. All non-Q wave AMI patterns required confirmation by abnormal peak enzyme levels, chest pain, or autopsy. Figure 1 presents the diagnostic algorithm for definite Q wave and non-Q wave AMI. The four major elements used to validate an AMI were 1) the presence or absence of acute chest pain, 2) peak levels of cardiac enzymes, 3) ECG patterns compatible with an AMI, and 4) the presence of an AMI by necropsy (AMI documented within 8 weeks of death). As AMIs.18-31 In-hospital case-fatality rates were statistically lower for non-Q wave AMI in half of the above studies (n=16).
Diagnostic Algorithm
The purpose of the MHS AMI diagnostic algorithm was to document in a standardized manner all acute AMI cases that occurred in the Twin Cities surveillance area. Because of this focus on community surveillance, we investigated four possible explanations for the higher non-Q wave AMI case-fatality rates observed in the present study. Third, we considered whether the Minnesota code classification of ECGs excluded small Q wave changes thought to be clinically important and subsequently misclassified some Q wave AMIs as non-Q wave AMIs. A cardiologist (R.C.) read each ECG identified by Minnesota code classification as non-Q wave AMI to determine whether clinical evaluation produced a different classification. Considering both years together, inclusion of the clinical reading resulted in reclassifying 13.3% of non-Q wave AMIs to Q wave AMIs. Case-fatality and 7-year survival rates were minimally affected by this reclassification, and none of the relations reported here was changed. In 1981, Marmor et al32,33 applied a diagnostic algorithm based on the Minnesota code to a sample group of 200 AMIs. Their definition of non-Q wave AMI was nearly identical to ours. They found case-fatality rates for Q wave AMIs higher than for non-Q wave AMIs. Bayley et a125 also used Minnesota code classification to diagnose survival and observed higher in-hospital case-fatality rates in Q wave AMI patients. Those results suggest that the differences in case-fatality rates observed in the present study are not primarily because of the sensitivity and specificity of AMI definition using Minnesota coded ECGs.
We also examined the likelihood that the MHS diagnostic algorithm's use of autopsy information may have differentially affected one type of AMI more than the other. In 1970 and 1980, significantly more non-Q wave AMIs than Q wave AMIs would have been excluded if autopsy findings were not considered. Exclusion of autopsy-identified AMIs significantly reduced non-Q wave AMI case-fatality rates and nonsignificantly reduced Q wave casefatality rates.
One possible explanation for the large effect of autopsy on non-Q wave AMI case fatality is that the MHS algorithm differentially mislabeled early Q wave cases that did not have time to evolve. When a definite AMI was found by autopsy, we documented non-Q wave AMI if there were at least two ECGs and no measurable Q wave on any ECG. Thus, an autopsy-confirmed recent AMI could be classified as a non-Q wave AMI when only one ECG in the hospital chart showed a nonspecific ST-T wave pattern. Conversely, if a single ECG showed a Q wave, the AMI could be classified as Q wave. In patients dying early, it is obvious that either Q wave or non-Q wave patterns could have evolved if death had not intervened. In the Beta-Blocker Heart Attack Trial,34 although the presence of abnormal Q waves was used to define the type of AMI, an ECG taken 5-21 days after the acute event showed that 17.4% of patients with Q wave AMIs lost their Q waves, whereas 32% of patients with non-Q wave AMIs developed significant Q waves during the interval. It 
Study Limitations
The present study is based on hospital record abstraction and did not include direct surveys of health-care providers, patients, or patients' families. Thus, it was not possible to verify symptoms or history of prior AMI. In the Twin Cities, patients do not necessarily return to the same hospital for care after an initial cardiac event. Because of these limitations, we were unable to differentiate between initial and recurrent MI events. Because of the reported higher prevalence of prior MI among non-Q wave patients, it is possible that our non-Q wave MI patients had a greater proportion of prior MIs than did those with Q wave MIs. We recognize that there also may be unexamined variables that contributed to the observed differences between Q wave and non-Q wave AMI mortality (i.e., cardiogenic shock, ventricular ectopy, location of Q wave MI, hypotension, heart block, and different therapeutic strategies for Q wave and non-Q wave AMI). Finally, some caution is warranted whenever enzyme levels are analyzed. The use of peak enzyme as a measure of equivalency of myocardial damage has limitations in that peak enzyme may not actually represent the true peak for that individual. The peak level depends on the time relation between MI onset to the time of enzyme collection. This information was not consistently available in the present study. Other measures of equivalency may include coronary anatomy, ejection fraction, and cardiac output. Categorical enzyme levels have been used for this purpose. Goldberg et a13 examined type of MI by tertile of peak CPK and found that case-fatality rates were lower among patients with non-Q wave MIs at each CPK level examined. We found that case-fatality rates for Q wave and non-Q wave AMI patients dichotomized by two enzyme categories were not statistically different in 1970 and 1980. We were surprised by the high case-fatality rates in 1970 among non-Q wave AMI patients with AST levels at least fivefold that of the upper limit of normal. These high rates may be due to the relatively small number of non-Q wave AMI patients in this category (n =50).
In summary, any study that uses hospital records faces certain limitations with regard to lack of availability of data that would ideally be collected in a prospective clinical trial and MI registry. We acknowledge the limitations of hospital record data and suggest the optimal strategy to minimize these limitations is to apply standardized approaches to collecting, categorizing, and interpreting the data.
Conclusions
Four important trends for community AMI rates are at variance with those reported by others. There was a decline in non-Q wave AMI attack rates from 1970 to 1980; women had an outcome equal to or worse than that of men for both case-fatality and 7-year survival rates; non-Q wave AMIs had worse in-hospital prognoses than Q wave AMIs; and 7-year survival was worse for patients with Q wave AMIs in 1980.
We believe the reason for our differing results is that the MHS used a standardized and consistent diagnostic algorithm instead of clinical judgment. The MHS diagnostic algorithm also classifies ECGs according to Minnesota code as part of its diagnostic structure. This ECG classification system provides comparability to other studies and minimizes ascertainment bias by eliminating the clinical judgment of referee cardiologists.
Montague et a137 pointed out that part of the present controversy about the significance of non-Q wave infarction derives from the clinical "use of ill-defined pathological nomenclature." Even though there now appears to be a consensus that a non-Q wave infarction is determined by the absence of "infarct-associated Q waves" on the ECG, unless the same criteria are used, different subgroups of non-Q wave AMI patients may be identified. The MHS adopted a case definition for the type of AMI that classified all AMIs, even those with minimal ECG information. Although the MHS used a "wide net" approach to identify events, the application of consistent diagnostic criteria over time resulted in an observed significant decrease in non-Q wave attack rates between 1970 and 1980. Other community surveillance based on all available clinical data has shown increasing non-Q wave attack rates during this decade. Again, these findings clearly demonstrate the need for standard diagnostic criteria for Q wave and non-Q wave AMIs if changes over time are to be monitored. In the future, as new trials of operative and nonoperative therapies in patients with AMIs are undertaken, these conditions will increase in importance.
